case_images: PMC6091473_01
case_images: H&E staining (A), 100x, and immunohistochemistry (B) for TTF-1, (C) for CK7, (D) for Napsin A, 100x, of the specimen, which showed lung adenocarcinoma.
case_images: ott-11-4739Fig1.jpg
case_images: PMC6091473_01_ott-11-4739Fig1.jpg
case_images: f1-ott-11-4739
case_images: H&E staining showed morphology typical of adenocarcinoma cells (Figure 1A). Immunohistochemistry demonstrated strong positivity for CK7, and weak staining of TTF-1, Napsin A (Figure 1B-D).
case_images: Next-generation sequencing showed R670W in epidermal growth factor receptor exon 17 (A), and H835L, L833V (B), and T790M (C) in exon 21.
case_images: ott-11-4739Fig2.jpg
case_images: PMC6091473_01_ott-11-4739Fig2.jpg
case_images: f2-ott-11-4739
case_images: The results showed that the patient had 3 uncommon EGFR mutations: EGFR-R670W in exon 17, H833V in exon 21, and H835L in exon 21 (Figure 2).
case_images: Treatment of lung adenocarcinoma using different regimens, and the results of monitoring the NGS of cfDNA.. Abbreviations: NGS, next-generation sequencing; cfDNA, cell-free DNA.
case_images: ott-11-4739Fig3.jpg
case_images: PMC6091473_01_ott-11-4739Fig3.jpg
case_images: f3-ott-11-4739
case_images: The patient was treated with oral gefitinib (250 mg, q.d.) on September 25, 2016 (Figure 3). The last follow-up was on January 24, 2018, at which point both the primary and metastatic brain lesions were stable, and T790M, H835L, and L833V disappeared (Figure 3).